IPO Watch: Indira IVF Hospital Files IPO Papers Worth ₹3,500 Crore via Confidential Route

Indira IVF Hospital, one of India’s leading fertility service providers, has initiated the process for an initial public offering (IPO) valued at ₹3,500 crore through the confidential route, as per news report. This move enables the company to tap capital markets while allowing shareholders to exit strategically.

Indira IVF’s ₹3,500 Crore IPO 

As per Bloomberg report, The upcoming IPO from Indira IVF will not involve the issue of fresh equity shares. Instead, it will be a complete offer for sale (OFS) by existing stakeholders. EQT, a notable private equity investor, plans to divest around ₹2,900 crore worth of shares. Additionally, founders Ajay Murdia, Kshitiz Murdia, and Nitiz Murdia will each offload shares worth ₹200 crore. This listing strategy gives liquidity to investors without diluting existing equity.

What is the Confidential Filing Route?

By opting for the confidential filing route with SEBI, Indira IVF can submit its draft offer documents privately and seek regulatory feedback before going public. This mechanism grants companies strategic flexibility in terms of market timing and confidential handling of sensitive business information.

Company Background and Market Position

Established in 2011, Indira IVF operates more than 155 fertility clinics nationwide and collaborates with over 315 IVF specialists. The company is widely recognised for its significant market share in India’s rapidly expanding Assisted Reproductive Technology (ART) segment. Its geographic coverage and medical expertise position it as a dominant player in reproductive healthcare services across urban and semi-urban locations.

Read More: Manipal Hospitals Seals ₹6,000 Crore Deal to Acquire Pune-based Sahyadri Hospitals!

Other IPOs Filed via Confidential Route

Indira IVF joins a growing list of Indian companies choosing the confidential IPO route, including INOX Clean Energy, Shadowfax Technologies, boAt, Tata Capital, and PhysicsWallah. This trend indicates a strategic shift in how companies approach public fundraising with a focus on timing and privacy.

Conclusion

Indira IVF’s ₹3,500 crore IPO is set to be one of the largest in the fertility healthcare space and will offer a complete exit opportunity to existing shareholders. The confidential filing approach aligns well with the company’s strategy, offering better control over the process and market readiness.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities are subject to market risks. Read all related documents carefully before investing.